with stirring sufficient water is then added to produce the required volume the solution of the above ingredients is administered intravenously at a rate of for example 1 ml minute the compositions and products of the invention can be administered to the human or animal body by various routes including the oral rectal transdermal subcutaneous intravenous intramuscular or intranasal routes if gemcitabine hydrochloride is the active ingredient it is preferably administered via the iv route dosages per day will normally fall within the range of about 0 01 to about 10 mg kg of body weight bw in single or divided doses preferably dosages per day range from about 0 025 to about 5 mg kg and most preferably from about 0 05 to 0 25 mg kg however it will be understood that the amount of compound actually administered will be determined by a physician in the light of the relevant circumstances including the condition to be treated the particular compound to be administered the chosen route of administration the age weight and response of the individual patient and the severity of the patient s symptoms and therefore the above dosage ranges are not intended to limit the scope of the invention.